Education
About Us
Working with TipRanks
Follow Us
AbSci (ABSI)
NASDAQ:ABSI
Earnings Data
Report Date
Aug 19, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.21Last Year’s EPS
-0.22Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: -5.74%
|Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant milestones, including the initiation of clinical trials and a robust financial position. Despite increased expenses and modest revenue, the company's strategic focus on AI-driven drug discovery and potential partnerships indicates a positive outlook.Company Guidance
In the recent call, Absci provided detailed guidance on their progress and future plans. The company announced the initiation of their first-in-human clinical trial for ABS-101, which is now in a Phase I study involving approximately 40 healthy adult volunteers. The trial aims to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), with interim results expected later this year. Additionally, Absci is advancing ABS-201, an anti-prolactin receptor antibody, with a Phase I trial slated for early 2026 and interim efficacy data by the end of that year. The company reported Q1 2025 revenue of $1.2 million, with R&D expenses at $16.4 million, up from $12.2 million the previous year, and SG&A expenses at $9.5 million. Absci ended the quarter with $134 million in cash and short-term investments, projecting sufficient funding into the first half of 2027. The company also expressed optimism about potential partnerships, including with large pharmaceutical companies, and emphasized their commitment to leveraging AI for drug discovery.Initiation of First-in-Human Clinical Trial
Absci initiated its first-in-human clinical trial for ABS-101, marking its transition to a clinical-stage biotech company. The trial focuses on safety and tolerability, with interim results expected later this year.
Strong Financial Position
Absci ended the quarter with $134 million in cash, cash equivalents, and short-term investments, up from $112.4 million at the end of 2024. The company expects these funds to support operations into the first half of 2027.
AI-Driven Drug Discovery Advancements
Absci's generative AI platform continues to accelerate the development of therapeutics, with promising progress in AI-designed antibodies for unmet medical needs.
Partnership and Collaboration Prospects
Absci anticipates signing one or more drug creation partnerships this year, including with a large pharma company, leveraging its AI platform.
ABSI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ABSI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $2.96 | $2.91 | -1.69% |
Mar 18, 2025 | $3.08 | $2.98 | -3.25% |
Nov 12, 2024 | $4.28 | $3.64 | -14.95% |
Aug 14, 2024 | $3.73 | $4.14 | +10.99% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does AbSci (ABSI) report earnings?
AbSci (ABSI) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
What is AbSci (ABSI) earnings time?
AbSci (ABSI) earnings time is at Aug 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABSI EPS forecast?
ABSI EPS forecast for the fiscal quarter 2025 (Q2) is -0.21.